Approved policies, procedures and guidelines
- MU IBC Charter (Revised - 1/19/2023)
- MU IBC Policy Statement on Toxins of Biological Origin (Revised - 8/13/2013)
- MU IBC Policy Statement on Human/Nonhuman Primate Cell Lines (Revised - 8/17/2023)
- MU IBC Policy Statement on Transgenic Animals (Revised - 9/21/2023)
- MU IBC Core Facility Guidelines (Revised - 8/15/2024)
- MU IBC Policy Statement on Transgenic Plants (Revised - 5/18/2023)
- MU IBC Policy on Handling Lentivirus, Adenovirus and AAV-Based Vectors (Revised - 04/26/2023)
- MU IBC Human Gene Transfer Trials Serious Adverse Event Reporting Policy (Adopted - 11/21/2013)
- MU IBC Policy on IBC Meeting Minutes (Revised - 10/19/2023)
- MU IBC Policy on Redacting IBC Meeting Minutes (Adopted - 2/16/2024)
- MU IBC Policy on Receipt and Transmission of Public Comments (Adopted - 2/16/2024)
- MU IBC Conflict of Interest Policy (Revised - 6/19/2024)
- MU IBC Dual Use Research of Concern (DURC) (Adopted - 9/17/2015)
- MU IBC Policy on Renewals, Suspensions, and Terminations of Protocols (Revised - 8/18/2022)
- MU Vaccination Policy and Surveillance Guidelines (login required) (approved by IBC 3/17/2022)
Contact us
Email: ibc@missouri.edu Phone: 573-882-3148